Compare IDEXX Laboratories, Inc. (IDXX) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Under Armour Inc Class A — how do they compare? IDEXX Laboratories, Inc. trades at $552.03 (market cap $44.48B), while Under Armour Inc Class A trades at $7.13 (market cap $3.07B). The key difference: IDEXX Laboratories, Inc. is far larger — about 14.5× Under Armour Inc Class A's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | UA | |
|---|---|---|
Market Cap | $44.48B | $3.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $7.88 |
52-Week Low | $520.87 | $3.96 |
Enterprise Value | $45.38B | $4.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Under Armour (UA) trades at $7.13, down 2.06% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $201.27 million for 2025, with revenue of $5.16 billion, and faces declining revenue projections for 2026. Recent news includes a Dodge collaboration and an upcoming Q1 2027 earnings call on August 7, 2026.
The outlook remains challenged by negative profitability and cash flow, though analyst consensus leans slightly bullish with 40.3% buy ratings. Key risks include sustained revenue declines and high debt, while potential upside hinges on successful execution of premium product focus and inventory management strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
